SPECIALIZED PRESS July 21, 2021 Not intended for U.S. and UK MediaBayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EURead more
July 19, 2021 BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s DiseaseRead more
SPECIALIZED PRESS July 9, 2021 Not intended for U.S. and UK MediaU.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetesRead more
June 29, 2021 Bayer Carbon Initiative:Bayer launches its decarbonization program for agriculture in EuropeRead more
SPECIALIZED PRESS June 23, 2021 Not intended for U.S. and UK MediaRivaroxaban application submitted to U.S. FDA for approval to treat VTE and to prevent VTE in children Read more
SPECIALIZED PRESS June 23, 2021 Not intended for U.S. and UK MediaVericiguat approved in Japan to treat patients with chronic heart failureRead more
SPECIALIZED PRESS June 21, 2021 Not intended for U.S. and UK MediaBayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EURead more
